Holen Sie sich die Stockscreener-App
1.45
4.32%
0.06
Schlusskurs vom Vortag:
$1.39
Offen:
$1.42
24-Stunden-Volumen:
1.01M
Relative Volume:
0.29
Marktkapitalisierung:
$135.61M
Einnahmen:
$32.31M
Nettoeinkommen (Verlust:
$-237.09M
KGV:
-0.5035
EPS:
-2.88
Netto-Cashflow:
$-219.11M
1W Leistung:
-11.59%
1M Leistung:
+26.09%
6M Leistung:
-53.53%
1J Leistung:
-73.92%
1-Tages-Spanne:
$1.41
$1.53
1-Wochen-Bereich:
$1.29
$1.6488
52-Wochen-Spanne:
$0.9101
$6.69
Editas Medicine Inc Stock (EDIT) Company Profile
Firmenname
Editas Medicine Inc
Sektor
Branche
Telefon
617-401-9000
Adresse
11 HURLEY ST., CAMBRIDGE, MA
Vergleichen Sie EDIT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EDIT
Editas Medicine Inc
|
1.45 | 135.61M | 32.31M | -237.09M | -219.11M | -2.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
431.54 | 128.25B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
538.92 | 63.70B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
551.97 | 39.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.12 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.21 | 27.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-12-16 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-12-13 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-12-13 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-13 | Herabstufung | Truist | Buy → Hold |
| 2024-12-11 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-11-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-11-04 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-08-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-05-09 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-24 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-10-18 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-10-17 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-29 | Hochstufung | Stifel | Hold → Buy |
| 2023-06-12 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-13 | Eingeleitet | Citigroup | Neutral |
| 2022-12-06 | Fortgesetzt | Credit Suisse | Neutral |
| 2022-11-18 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-11-18 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-09-29 | Eingeleitet | BofA Securities | Neutral |
| 2021-10-19 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2021-09-24 | Eingeleitet | Stifel | Hold |
| 2021-09-10 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-08-09 | Hochstufung | Truist | Hold → Buy |
| 2021-08-05 | Hochstufung | Evercore ISI | Underperform → Outperform |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-04-16 | Eingeleitet | Goldman | Sell |
| 2021-03-22 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-01 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-02-26 | Herabstufung | Truist | Buy → Hold |
| 2021-01-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-01-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-12-10 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-11-03 | Eingeleitet | Robert W. Baird | Underperform |
| 2020-06-18 | Fortgesetzt | SunTrust | Buy |
| 2020-02-21 | Eingeleitet | Wells Fargo | Equal Weight |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-10-10 | Eingeleitet | Guggenheim | Neutral |
| 2018-09-21 | Eingeleitet | Raymond James | Outperform |
| 2018-05-15 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-02-13 | Eingeleitet | CLSA | Underperform |
| 2018-01-23 | Hochstufung | SunTrust | Hold → Buy |
| 2017-07-14 | Eingeleitet | SunTrust | Hold |
| 2017-03-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-08-10 | Hochstufung | Jefferies | Hold → Buy |
| 2016-06-02 | Eingeleitet | Jefferies | Hold |
| 2016-02-29 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-02-29 | Eingeleitet | JP Morgan | Neutral |
| 2016-02-29 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Editas Medicine Inc Aktie (EDIT) Neueste Nachrichten
Editas Medicine (EDIT) to Release Quarterly Earnings on Wednesday - MarketBeat
Zacks Research Comments on Editas Medicine FY2027 Earnings - MarketBeat
Genome Editing Market Future Business Opportunities 2025-2032 - openPR.com
Susquehanna Fundamental Investments LLC Acquires New Stake in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
HC Wainwright Estimates Editas Medicine Q1 Earnings - MarketBeat
Cantor Fitzgerald Upgrades Editas Medicine (NASDAQ:EDIT) to "Strong-Buy" - MarketBeat
Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May - GlobeNewswire
Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor ... - Bluefield Daily Telegraph
Editas Medicine Earnings Alert: Q1 2025 Results Coming May 12, Ends Quarterly Calls - Stock Titan
Editas Medicine (NASDAQ:EDIT) Stock Rating Upgraded by HC Wainwright - MarketBeat
Editas Medicine, Inc. (NASDAQ:EDIT) Receives $6.83 Consensus Target Price from Analysts - MarketBeat
Editas Medicine Inc expected to post a loss of 58 cents a shareEarnings Preview - TradingView
Renaissance Technologies LLC Purchases New Position in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
HC Wainwright & Co. Initiates Coverage of Editas Medicine (LSE:0IFK) with Buy Recommendation - Nasdaq
Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Barchart.com
Editas Medicine (EDIT) Receives Positive Coverage from H.C. Wain - GuruFocus
HC Wainwright & Co. Initiates Coverage of Editas Medicine (EDIT) with Buy Recommendation - Nasdaq
Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting | EDIT Stock N - GuruFocus
Editas Medicine to Present Five Abstracts at the 28th Annual Meeting of the American Society of Gene and Cell Therapy - Nasdaq
Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting - The Manila Times
Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in ... - Bluefield Daily Telegraph
Editas Unveils Game-Changing In Vivo Gene Editing Breakthroughs: 5 Major Studies at ASGCT 2025 - Stock Titan
Recent uptick might appease Editas Medicine, Inc. (NASDAQ:EDIT) institutional owners after losing 71% over the past year - simplywall.st
Press Release Distribution & PR Platform - ACCESS Newswire
Leerink Partnrs Forecasts Editas Medicine Q3 Earnings - MarketBeat
Cell and Gene Therapy Market Investment Trends & Emerging - openPR.com
Editas Medicine, Inc. (NASDAQ:EDIT) institutional owners may be pleased with recent gains after 71% loss over the past year - Yahoo Finance
Leerink Partnrs Weighs in on Editas Medicine Q1 Earnings - MarketBeat
New Horizons in Biomedical CRISPR Gene Editing Market Exploring - openPR.com
Leber Congenital Amaurosis Market to Show Remarkable Growth - openPR.com
Raymond James Financial Inc. Takes $303,000 Position in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
Genome Editing Market Growth 2025: Trends, Consumer Demand, - openPR.com
SEC Form PRE 14A filed by Editas Medicine Inc. - Quantisnow
Why Is Editas (EDIT) Down 37.1% Since Last Earnings Report? - Yahoo Finance
Editas Medicine: Do The Risks Outweigh The Rewards? (NASDAQ:EDIT) - Seeking Alpha
Top 5 CRISPR Companies To Invest In (May 2025) - Securities.io
Editas Medicine (EDIT) Reports Q4 Loss, Misses Revenue Estimates - MSN
Editas Medicine stock hits 52-week low at $1.12 amid sharp decline - Investing.com
Editas Medicine stock hits 52-week low at $1.12 amid sharp decline By Investing.com - Investing.com South Africa
RNA Pioneer and Former Editas CEO Joins Codexis Board: Strategic Move for RNA Therapeutics Push - Stock Titan
Finanzdaten der Editas Medicine Inc-Aktie (EDIT)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.11%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):